Stability in the production and transport of 177Lu labelled PSMA
DOI:
https://doi.org/10.15392/bjrs.v9i1.1619Keywords:
production of 177Lu-PSMA-617, radiopharmaceutical stability, industrial radiopharmacy center.Abstract
The prostate cancer is the second most prevalent disease among men in Brazil, moreover PSMA therapy could change this scenario and its perspectives. IPEN-CNEN is the Brazilian industrial radiopharmacy center that produces radiopharmaceuticals for therapy. The production of 177Lu-PSMA-617 was evaluated in batches until 37 GBq and showed that the combination of ascorbate buffer, adequate radioactive concentration and freezing promoted the stability of the radiopharmaceutical for 48 hours, enabling transport of 177Lu-PSMA-617 to distant regions of the country.Downloads
References
INCA. INSTITUTO NACIONAL DO CÂNCER. Câncer de próstata. Disponível em: <https://www.inca.gov.br/tipos-de-cancer/cancer-de-prostata>. Acesso em: 17 jun. 2020.
LIU, S.; ELLARS, C.E.; EDWARDS, D.S. Ascorbic acid: Useful as a buffer agent and radiolytic stabilizer for metalloradiopharmaceuticals. Bioconjugate Chemistry, v. 14, n. 5, p. 1052–1056, 2003.
MAUS, S. et al. Aspects on radiolabeling of 177Lu-DOTA-TATE: After C18 purification re-addition of ascorbic acid is required to maintain radiochemical purity. International Journal of Diagnostic Imaging, v. 1, n. 1, p. 5, 2014.
REILLY, R.M. Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2010.
AGENCIA NACIONAL DE VIGILÂNCIA SANITÁRIA. Resolução da Diretoria Colegiada - RDC No 301, de 21 de agosto de 2019. Disponível em: <http://portal.anvisa.gov.br/documents/10181/5389382/RDC_301_2019_.pdf/2e049461-1e8a-4bbb-8e09-8d3c04dea07d>. Acesso em: 5 jan. 2020.
BREEMAN, W.A.P. et al. The addition of DTPA to[177Lu-DOTA0, Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity. European Journal of Nuclear Medicine and Molecular Imaging, v. 30, n. 2, p. 312–315, 2003.
PRICE, E.W.; ORVIG, C. Matching chelators to radiometals for radiopharmaceuticals. Chemical Society Reviews, v. 43, n. 1, p. 260–290, 2014.
BREEMAN, W.A.P. et al. Overview of Development and Formulation of 177 Lu-DOTA-TATE for PRRT. Current Radiopharmaceuticals, v. 9, n. 1, p. 8–18, 23 nov. 2015.
DE ZANGER, R.M.S. et al. Maintaining radiochemical purity of [177Lu]Lu-DOTA-PSMA-617 for PRRT by reducing radiolysis. Journal of Radioanalytical and Nuclear Chemistry, v. 321, n. 1, p. 285–291, 2019.
WAHL, R.L. et al. Inhibition of autoradiolysis of radiolabeled monoclonal antibodies by cryopreservation. Journal of Nuclear Medicine, v. 31, n. 1, p. 84–89, 1990.
Published
Issue
Section
License
Copyright (c) 2021 Brazilian Journal of Radiation Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing: The BJRS articles are licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
How to Cite
